| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 16th February 2021 | Thomas Gad | 4,000 | Open or private sale | $47.09 | $188,366.80 |
| 16th February 2021 | Thomas Gad | 7,000 | Open or private sale | $47.08 | $329,555.80 |
| 16th February 2021 | Thomas Gad | 7,000 | Exercise of derivative | $2.00 | $14,000.00 |
| 9th February 2021 | James Healy | 450,000 | Open or private purchase | $20.00 | $9,000,000.00 |
| 9th February 2021 | James Healy | 1,200,228 | Conversion of derivative | $0.00 | |
| 9th February 2021 | James Healy | 1,104,209 | Conversion of derivative | $0.00 | |
| 19th January 2021 | David N Gill | 2,000 | Exercise of derivative | $11.16 | $22,320.00 |
| 19th January 2021 | Thomas Gad | 7,000 | Exercise of derivative | $2.00 | $14,000.00 |
| 19th January 2021 | David N Gill | 2,000 | Open or private sale | $46.52 | $93,045.20 |
| 19th January 2021 | Thomas Gad | 4,000 | Open or private sale | $46.56 | $186,230.40 |
Y M Abs Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory.
Ticker: YMAB
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1722964
Employees: 32
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $158 M (0%)
Other Assets, Current: $5 M (9%)
Assets, Current: $163 M (-22%)
Property, Plant and Equipment, Net: $2 M (-7%)
Other Assets, Noncurrent: $357 Th (-3%)
Assets: $167 M (-22%)
Accounts Payable, Current: $10 M (15%)
Accrued Liabilities, Current: $5 M (0%)
Liabilities, Current: $16 M (15%)
Other Liabilities, Noncurrent: $2 M (614%)
Liabilities: $21 M (22%)
Common Stock, Value, Issued: $4 Th (0%)
Common Stock, Shares, Issued: $40 M (0%)
Retained Earnings (Accumulated Deficit): $232 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $16 Th (-68%)
Stockholders' Equity (Parent): $146 M (0%)
Liabilities and Equity: $167 M (-22%)
Research and Development: $30 M (-38%)
General and Administrative Expenses: $10 M (-43%)
Operating Income/Loss: $40 M (-39%)
News
Y-mAbs Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
26th February 2021
Y-mAbs Announces Pricing of Public Offering of Common Stock
18th February 2021